SNCAIP Protein

SNCAIP Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SNCAIP Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>SNCAIP / synphilin-1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>SNCAIP</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5L4</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~91 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytoplasm, membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Phospholipase D family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">265 edges</a></td>
</tr>
</table>

Pathway Diagram

SNCAIP Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SNCAIP Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>SNCAIP / synphilin-1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>SNCAIP</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5L4</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~91 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytoplasm, membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Phospholipase D family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">265 edges</a></td>
</tr>
</table>

Pathway Diagram

Sncaip Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SNCAIP Protein (Synuclein Alpha Interacting Protein), also known as Phospholipase D6, is a protein that directly interacts with [alpha-synuclein](/mechanisms/alpha-synuclein) and plays a critical role in the pathogenesis of Parkinson's disease and other synucleinopathies. [@engelender1999]

Protein Information

Structure

SNCAIP contains several functional domains:

• N-terminal coiled-coil domain: Protein-protein interactions
• Ankyrin repeat domain: Binding interactions
• PLD domain (aa 400-750): Phospholipase activity
• Hydrophobic regions: Membrane association

Normal Function

SNCAIP functions as:

• [Alpha-synuclein](/proteins/alpha-synuclein) binding protein
• Modulates alpha-synuclein aggregation
• Involved in membrane trafficking
• Has phospholipase D activity
• Regulates autophagy
• May have neuroprotective functions

Role in Disease

Parkinson's Disease

• Gene duplication/triplication: Causes familial PD
• Promotes alpha-synuclein aggregation
• Found in Lewy bodies
• Interferes with autophagy-lysosomal pathway
• Contributes to dopaminergic neuron death

Dementia with Lewy Bodies

• Interacts with Lewy body alpha-synuclein
• May influence disease progression

Therapeutic Targeting

• Interaction inhibitors: Blocking SNCAIP-alpha-synuclein binding
• PLD inhibitors: Modulating lipid signaling
• [Autophagy](/entities/autophagy) enhancers: Clearing aggregates

Key Publications

External Links

• [UniProt: SNCAIP](https://www.uniprot.org/uniprot/Q9Y5L4)
• [PDB: SNCAIP domain structure](https://www.ebi.ac.uk/pdbe/)

Molecular Interactions

Interaction with Alpha-Synuclein

SNCAIP (Synphilin-1) was originally identified as an interacting partner of alpha-synuclein:

• Binding domains: SNCAIP binds to the NAC domain (residues 61-95) of alpha-synuclein
• Co-aggregation: SNCAIP co-aggregates with alpha-synuclein to form Lewy bodies
• Cytoplasmic inclusions: Promotes formation of cytoplasmic inclusion bodies
• Cellular toxicity: Overexpression enhances alpha-synuclein toxicity in models

Protein Structure

SNCAIP contains several functional domains:

• Coiled-coil domains: Mediate protein-protein interactions
• SANT domains: DNA mimicry for transcriptional regulation
• LZIP domain: Leucine zipper for dimerization

Brain Region Expression

SNCAIP shows region-specific expression:

• High expression: Substantia nigra pars compacta (dopaminergic neurons)
• Moderate: Cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus)
• Lower: Cerebellum, brainstem

Disease Mechanisms

Parkinson's Disease

• Lewy body component: SNCAIP is a major component of Lewy bodies
• Aggregation promotion: Facilitates alpha-synuclein oligomerization
• Genetics: SNCAIP polymorphisms associated with PD risk
• Selective vulnerability: High expression in susceptible neuron populations

Dementia with Lewy Bodies

• Pathology: SNCAIP-positive inclusions in cortical [neurons](/entities/neurons)
• Co-pathology: Often co-occurs with Alzheimer's pathology
• Clinical correlation: Inclusion density correlates with cognitive decline

Multiple System Atrophy

• Glial cytoplasmic inclusions: SNCAIP found in oligodendroglial inclusions
• Different pattern: More widespread than in PD/DLB

Therapeutic Implications

Target Development

• Aggregation inhibitors: Prevent SNCAIP-alpha-synuclein interaction
• Protein-protein interaction blockers: Small molecules disrupting complex formation
• Gene therapy: siRNA approaches to reduce SNCAIP expression
• Vaccination: Immunotherapy targeting SNCAIP-containing aggregates

Biomarker Potential

• CSF levels: Detectable in cerebrospinal fluid
• Peripheral biomarkers: Blood and tissue expression studies ongoing

Research Methods

Biochemical Approaches

• Co-immunoprecipitation
• Mass spectrometry for complex identification
• Surface plasmon resonance for binding kinetics

Cellular Models

• Transgenic cell lines overexpressing SNCAIP
• Primary neuron cultures
• Patient-derived iPSC neurons

Animal Models

• Transgenic mouse models
• AAV-mediated overexpression
• Knockout and conditional knockout models

Background

The study of Sncaip Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

See Also

• [SNCAIP Gene](/genes/sncaip)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)